What is IVVD's current stock price?

IVVD (Invivyd, Inc.) is currently trading at $1.10 with a market cap of $146.0M.

What sector is Invivyd, Inc. in?

Invivyd, Inc. (IVVD) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IVVD a good stock to buy?

Analysts have a Buy consensus on IVVD with a price target of $9.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IVVD Invivyd, Inc.

Healthcare

$1.10-0.90%ClosedMarket Cap: $146.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.68

P/S

2.61

EV/EBITDA

0.37

DCF Value

$11.22

FCF Yield

-54.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

92.0%

Operating Margin

-146.4%

Net Margin

-138.9%

ROE

-53.5%

ROA

-32.1%

ROIC

-38.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$13.7M	$-41.4M	$—
Q4 null	$17.2M	$-11.1M	$—
FY null	$53.4M	$-52.5M	$—
Q3 null	$13.1M	$-10.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.50

Target (Median)

$9.50

Target Range

$9.00 - $10.00

0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

BTIGBuy

2026-05-18

BTIGBuy

2026-02-26

BTIGBuy

2025-12-23

D. Boral CapitalHold

2025-11-25

HC Wainwright & Co.Buy

2025-11-03

Trading Activity

Insider Trades

View All

Royan Ajaydirector

SellThu May 21

MCLAUGHLIN KEVIN Fdirector

SellThu May 21

MCGUIRE TERRANCEdirector

SellThu May 21

Elia Marcdirector, other: See Remarks

SellThu May 21

BOLNO PAULdirector

SellThu May 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.71

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Peers

SLS